ライフサイエンスコーパス: live birth

1 progeny by glandular secretions followed by live birth).

2 onatal mortality before age 28 days per 1000 live births).

3 ive mothers (9 infected newborns of 65 total live births).

4 ng pregnancy (31%; 9 infected newborns in 29 live births).

5 ian genetic diseases ( approximately 1/2,000 live births).

6 considerably reduced (0.13 (0.07-0.21)/1,000 live births).

7 llbirth has a similar immune cell profile to live birth.

8 late into higher probability of pregnancy or live birth.

9 periencing an uncomplicated pregnancy with a live birth.

10 tion rate, embryo quality, implantation, and live birth.

11 We focus on conceptions that result in a live birth.

12 ason that archosauromorphs could not achieve live birth.

13 ation on GDM diagnosis was obtained for each live birth.

14 ation, implantation, clinical pregnancy, and live birth.

15 cts of economic conditions on selection into live birth.

16 common birth defect, affecting about 0.8% of live births.

17 contributing to the monthly distribution of live births.

18 affecting approximately one in 10 000 female live births.

19 all neonatal mortality rate was 17 per 1,000 live births.

20 (iv) amniocentesis, and (v) fetal deaths and live births.

21 he United States in 2013 was 1.75 per 100000 live births.

22 -weight infants (<1500 g) was 844.1 per 1000 live births.

23 a reported incidence of 1 in 100,000-130,000 live births.

24 -child HIV transmission goal of 1 per 100000 live births.

25 ancy during the follow-up, which generated 3 live births.

26 ly reported, occurring in at least 1 in 6300 live births.

27 tal disorder affecting approximately 0.8% of live births.

28 ere combined immunodeficiency at 1 in 66,250 live births.

29 a high frequency in humans, affecting ~1:250 live births.

30 d the neonatal mortality rate is 33 per 1000 live births.

31 nd the under-5 mortality rate is 20 per 1000 live births.

32 een 2000 and 2010 from 0.28 to 0.41 per 1000 live births.

33 emonstrated an incidence of ONH of 1 in 2287 live births.

34 residents younger than 19 years or 1 in 2287 live births.

35 ing anomaly that affects approximately 1% of live births.

36 lantation had an acceptable outcome with 70% live births.

37 Data were available on 3017 live births.

38 een 1991 and 2010 from 0.11 to 0.29 per 1000 live births.

39 dence of GBS-associated NE of 0.019 per 1000 live births.

40 ost frequent birth defect, affecting 0.8% of live births.

41 disease (CHD), the most common defect among live births.

42 ital heart disease (CHD) affects up to 1% of live births.

43 ocephaly occurs in approximately 7 per 10000 live births.

44 articipants ranging between 6,125 and 29,901 live births.

45 sability in childhood and occurs in 1 in 500 live births.

46 Its overall incidence is 1 in 60000 live births.

47 childhood nephropathy, occurring 1 in 20,000 live births.

48 livery among mothers who have had at least 2 live births.

49 5.7%), 3 (18.6%), 4 (8.8%), and >/= 5 (5.9%) live births.

50 common birth defect occurring in 1 in 2,500 live births.

51 cavity, with a global incidence of 1 per 700 live births.

52 ) preterm live-births and 187,966 (9.1%) SGA live-births.

53 We studied 52,163 stillbirths and 10,238,950 live-births.

54 . 72 of 376 [19.1%], P=0.007; rate ratio for live birth, 1.44; 95% confidence interval, 1.10 to 1.87)

55 d RR, 0.95; 95% CI, 0.93-0.97), and multiple live birth (30.1% vs 31.0%; adjusted RR, 0.93; 95% CI, 0

56 5.2%; adjusted RR, 0.93; 95% CI, 0.91-0.95), live birth (36.5% vs 39.2%; adjusted RR, 0.95; 95% CI, 0

57 ntation (31%), clinical pregnancy (41%), and live birth (38%).

58 % CI: 101, 111) CS cases averted per 100,000 live births (58% decrease).

59 % CI: 154, 160) CS cases averted per 100,000 live births (85% decrease).

60 Of all live births, 9031 (27.0%) were early term.

61 iated with 7.9 fewer infant deaths per 1,000 live births (95% CI 3.7, 12.0), reflecting a 13% relativ

62 ncidence of severe sepsis was 4.9 per 10,000 live births (95% CI = 4.5-5.2).

63 s; incidence of all sepsis was 10 per 10,000 live births (95% CI = 9.4-10.3).

64 ted with an increase of 0.07 deaths per 1000 live births (95% CI, 0.01-0.13) the following year.

65 n delivery rate estimates up to 19.1 per 100 live births (95% CI, 16.3 to 21.9) and 19.4 per 100 live

66 rths (95% CI, 16.3 to 21.9) and 19.4 per 100 live births (95% CI, 18.6 to 20.3) were inversely correl

67 ive GBS disease in infants was 0.49 per 1000 live births (95% confidence interval [CI], .43-.56), and

68 in the first year of life was 8.21 per 1000 live births (95% confidence interval, 7.47-9.02) from 19

69 s (GBS) (150/302 [50%]; incidence, 0.16/1000 live births; 95% CI, .13-.18) and Escherichia coli (41/3

70 were identified (annual incidence, 0.38/1000 live births; 95% confidence interval [CI], .35-.42).

71 overwhelmingly preceded by the evolution of live birth across multiple independent origins of both t

72 The primary outcome was live birth after 24 weeks of gestation.

73 probability of pregnancy (P-trend = 0.83) or live birth after ART (P-trend = 0.47).

74 hazards model was used to investigate first live birth after diagnosis/referent date.

75 programs, 2 years after the first worldwide live birth after uterus transplantation.

76 nancy complications, but can have successful live births after having a poor outcome.

77 endometrial cancer and age at first and last live birth, age at menopause, and postmenopausal hormone

78 urpose To compare the probability of a first live birth, age at time of birth, and time between diagn

79 Reproductive factors (number of live births, age at first pregnancy, and total reproduct

80 D including age, pregnancy status, number of live births, age at menarche, menstrual irregularity, ag

81 trates reduced probability of having a first live birth among cancer survivors diagnosed during child

82 erences in the probability of having a first live birth among women diagnosed during adolescence (HR,

83 Reported singleton live births among 1,330 women after 1 January 2005 were

84 not result in a significantly higher rate of live births among women with a history of unexplained re

85 ster of pregnancy would increase the rate of live births among women with a history of unexplained re

86 ecame pregnant, compared with 16.4% (9 of 55 live births) among untreated mothers.

87 Here, we assessed the effect of LDA on male live birth and male offspring, incorporating pregnancy l

88 Whether AH significantly changes live birth and miscarriage rates needs further investiga

89 Incidence of pure NHS was 1 in 9500 live births and 1 in 6300 for all forms.

90 reductions of 1.0-1.6 cases of sPTB per 100 live births and 20%-30% reductions in risk of sPTB compa

91 were 21 infants with birth defects among 395 live births and 5 fetuses with birth defects among 47 pr

92 From 1997 to 2014, 970,583 live births and 6510 infant deaths were registered.

93 Ds) occur at a frequency of 1 in every 5,000 live births and are a common cause of pediatric neurodeg

94 ey and urinary tract are observed in 0.5% of live births and are a major cause of end-stage renal dis

95 ccur at a collective frequency of 1 in 5,000 live births and are caused by inherited defects in genes

96 ebral malformations (CVM) occur in 1 in 1000 live births and in many cases can cause spinal deformiti

97 CA occurs in approximately 1/5000 live births and is a frequent component of congenital di

98 ystemic lupus erythematosus (SLE) have fewer live births and more pregnancy complications, but can ha

99 a unique 10-digit identifier assigned to all live births and new residents in Denmark.

100 ith progesterone would increase the rates of live births and newborn survival among women with unexpl

101 idence interval [CI], 12.0-14.0) per 100 000 live births and PCV7 serotypes accounted for 44% (154/34

102 prior to conception restored numbers of male live births and pregnancy with male offspring among wome

103 tion-based cohort study (N=5 901 701) of all live births and stillbirths (including late-pregnancy te

104 rth outcomes surveillance study compared all live births and stillbirths with a gestational age of at

105 We test whether cumulative live births and the pace of reproduction are associated

106 Use of ART among all live births and use of certain ART procedures among ART

107 iphene, letrozole was associated with higher live-birth and ovulation rates among infertile women wit

108 6%) perinatal deaths, 116,043 (5.6%) preterm live-births and 187,966 (9.1%) SGA live-births.

109 A total of 2205 births (stillbirths and live births) and terminations of pregnancy at 22 through

110 Age at menarche, first and last live birth, and menopause; number of live births; hormon

111 up, 149 women became pregnant, 131 women had live births, and 16 women had several pregnancies, resul

112 locardiofacial syndrome) occurs in 1 of 4000 live births, and 60% to 70% of affected individuals have

113 hs, the infant mortality rate is 46 per 1000 live births, and the neonatal mortality rate is 33 per 1

114 Limitations: The study was based on live births, and the possibility that data on miscarriag

115 and cardiovascular system malformation among live births, and this risk is significantly higher in hi

116 lity rate in Andhra Pradesh was 44 per 1,000 live births, and was higher in the rural areas and triba

117 We enrolled cases with CL +/- P and 2 live births as controls at birth from the same hospital.

118 ss preterm births and preeclampsia, and more live births as they were treated with LMWH.

119 iple gestation but also a lower frequency of live birth, as compared with gonadotropin but not as com

120 The probability of successful pregnancy with live birth at 1 year and 2 years was 24.4% and 36.7%, re

121 atient had placental hemorrhage with preterm live birth at the 30th week, and 1 patient had minor ble

122 ed to select women who had vaginal singleton live births at least twice in Connecticut during 2000-20

123 The study evaluated live births at or after 35 weeks' gestation at 12 facili

124 a from cross-sectional surveys of women with live births (Bangladesh 398, Malawi: 900, Nepal: 615), g

125 Population-level analysis of live births before discharge, 1989-2012, was conducted f

126 t baseline in 2003 and reported at least one live birth between 2003 and 2012.

127 f cycles resulting in clinical pregnancy and live birth between women in the fourth versus first quar

128 y reduced from 35.0 to 30.5 deaths per 1,000 live births between 2007 and 2013 in the five districts,

129 We included 24,381 and 23,307 live births between July 2010 and June 2013 and 7,823 an

130 Primary outcomes were the proportion of live births born small for gestational age (SGA) or pret

131 % (95% CI, 64.8%-65.8%) of women achieving a live birth by the sixth cycle.

132 al heart failure and increases the number of live births by fivefold.

133 This ability to obtain live births by transplanting isolated primordial and pri

134 20 weeks of gestation during 2000-2005 using live birth certificate data from three states (Pennsylva

135 From live birth certificates from three states, we constructe

136 95% CI: 0.99, 2.65) times the probability of live birth compared with women in the lowest quartile (<

137 95% CI: 1.14, 3.62) times the probability of live birth compared with women in the lowest quartile (<

138 95% CI: 1.12, 3.29) times the probability of live birth compared with women with folate and vitamin B

139 All full-term live births comprised the birth cohort; this information

140 pending on the pollutant, a maximum of 4,632 live-birth controls and 3,328 live-birth, fetal-death, o

141 th or selectively terminated cases and 3,972 live-birth controls were enrolled.

142 The primary outcome was live birth during the treatment period.

143 Resident live births during 2000 to 2010 were included, and the a

144 There were 33,488 live births during the 3-year period, of which 29,741 ha

145 Among the 53704641 live births during the study period, an increase of euro

146 There were 87,501 singleton live births during the year, and 55.8% occurred out-of-h

147 Primary outcome measures include rates of live births, elective terminations, stillbirths, and con

148 tio of less than or equal to 100 per 100 000 live births; estimated minimum need for surgery in the 2

149 insecticide-treated nets [ITNs]) leading to live births fell by 37% (33%-41% 95% credible interval [

150 ximum of 4,632 live-birth controls and 3,328 live-birth, fetal-death, or electively terminated cases

151 d with oocyte yield, clinical pregnancy, and live birth following ART.

152 rtile were associated with decreased odds of live birth following IUI (adjusted odds ratio = 0.19; 95

153 ns were not associated with fertilization or live birth following IVF.

154 f cycles resulting in clinical pregnancy and live birth for individual DEHP metabolites.

155 lying the Quest HCV infection rate to annual live births from 2011 to 2014 resulted in an estimated a

156 x mothers, with no difference in the rate of live births, gestational age, or small for gestational a

157 analysis was conducted on April 1, 2015, of live births (>/=500 g) from January 1, 2007, to December

158 Live birth has evolved many times independently in verte

159 s Overall, the probability of having a first live birth (hazard ratio [HR]) was significantly lower;

160 nd last live birth, and menopause; number of live births; hormonal contraceptive use; and postmenopau

161 ed in 35.5%, 28.3%, and 22.4% of cycles, and live birth in 32.2%, 23.3%, and 18.7%, respectively; pre

162 illion years ago) of southwest China showing live birth in archosauromorphs.

163 once daily) did not improve the chance of a live birth in nonthrombophilic women with unexplained re

164 Amongst the 7,823 women with a live birth in the year prior to survey in intervention w

165 to assemble a panel of approximately 300,000 live births in 20 countries from 2000 to 2008; these obs

166 strict 5q0 declined from 99 deaths per 1,000 live births in 2000 to 70 in 2010.

167 l stillbirths and a representative sample of live births in 59 hospitals in five geographic areas in

168 ased cohort study, we matched records of all live births in Arkansas with state-mandated data on chil

169 vital statistics records data for 1,622,474 live births in California during 2005-2007.

170 We conducted a cohort study of all singleton live births in Denmark from 1996 through 2005 (626,875 b

171 cephalopathy (HIE) occurs in 1 to 8 per 1000 live births in developed countries.

172 prevalence of FASD weighted by the number of live births in each country was estimated.

173 45,345 offspring, representing all singleton live births in Finland between 1996 and 2010.

174 ation-based nested case-control study of all live births in Finland from 1983 to 1998.

175 the neonatal mortality (day 0-27) per 1,000 live births in intervention and comparison wards based o

176 More than 25% of live births in low- and middle-income countries are at f

177 live births in singletons and 5.1 per 10,000 live births in multiples.

178 e KIDS Study) enrolled mothers who delivered live births in New York (2008-2010).

179 ion, and year of delivery) who had singleton live births in Quebec, Canada (1990-2007).

180 s during the study period was 3.6 per 10,000 live births in singletons and 5.1 per 10,000 live births

181 Follow-up of all live births in Sweden between 1992 and 2005, defined in

182 ased cohort study consisted of all singleton live births in Sweden from January 1, 1982, through Dece

183 July 2010 and June 2013 and 7,823 and 7,555 live births in the last year in intervention and compari

184 iated with a decline of 0.23 deaths per 1000 live births in the same year (95% CI, -0.37 to -0.09) an

185 h outcomes, using natality data on singleton live births in the United States during 1990-2013.

186 ortality and morbidity, affecting >1% of all live births in the Western world, yet a large fraction o

187 The majority of live births in this species are twins, and comparison of

188 The rate of live births in women with LT was higher than that in wom

189 tality; there were 764 deaths (54.0 per 1000 live births) in the iron-folic acid group and 741 deaths

190 lic acid group and 741 deaths (51.6 per 1000 live births) in the multiple micronutrient group (relati

191 placebo group, and the effect of LDA on male live birth increased (first tertile: 48% male in LDA vs.

192 However, live birth is unknown in the major clade Archosauromorph

193 (RTT), which affects approximately 1:10.000 live births, is a X-linked pervasive neuro-developmental

194 ith LDA, 543 treated with placebo), the male live birth ITT RR equaled 1.31 (95% CI: 1.07-1.59).

195 The study featured 625,042 live births linked with school records, including more t

196 th the number of maternal deaths per 100 000 live births (maternal mortality ratio; MMR) in WHO membe

197 erapy (MHT) use, other MHT use, age at first live birth, menopausal status, age at menopause, family

198 3 revision of the US Standard Certificate of Live Birth (N = 17,896,048).

199 ational diabetes mellitus was 318 per 10 000 live births (n=232) in comparison with a baseline risk o

200 Live births occurred in 76% of pregnancies in child-tx m

201 We conducted a population study of all live births occurring in England and Wales between 1 Jan

202 Exposure: Live birth of an infant with a major congenital anomaly

203 uring pregnancy, 8.8 months), there were 156 live births of 160 infants (4 twin pairs), 1 fetal death

204 the temporal and regional variations in the live births of the UK population, there was a significan

205 for temporal and regional variations in the live births of the UK population.

206 overall CHD prevalence was 116.2 per 10,000 live births, of which the severe CHD rate was 22.3 per 1

207 .1), excluding a 10% increase in the rate of live-birth on enoxaparin (P = .34).

208 % CI 1.10-1.47), types of controls included (live birth OR 2.82 95% CI: 1.64-4.86).

209 ase containing 376 154 pregnancies ending in live birth or stillbirth from women aged 15 to 44 years

210 63 women with at least 1 pregnancy ending in live birth or stillbirth in Denmark, 1978-2012, with fol

211 A total of 662 live-birth or selectively terminated cases and 3,972 liv

212 ancy or up to 42 days postpartum per 100,000 live births) or neonatal mortality rates (neonatal morta

213 The primary outcomes were adverse live birth outcome (composite of small for gestational a

214 The prevalence of adverse live birth outcome was similar in the ISTp-DP (29.9%) an

215 e reported incidence (3.27 cases per 100 000 live births overall; 95% confidence interval [CI], 2.73-

216 the body, occurs with a frequency of about 2 live births per 100 000 newborns although this incidence

217 g disease (HSCR) is approximately 15/100 000 live births per newborn but has been reported to show si

218 In Brazil, where there are 3 million live births per year, the application of this definition

219 Pregnancy incidence, birth outcomes (live births, pregnancy loss, preterm birth, congenital a

220 tal prevalence of syphilis, annual number of live births, proportion of women with at least one anten

221 The primary outcome was the live birth rate and secondary outcomes included gestatio

222 The live birth rate in the Canadian cohort (86.4%) was signi

223 The overall live birth rate per embryo transfer was similar to the U

224 Live birth rate was 19.2% and lowest average SPTRX3 leve

225 potential of preimplantation embryos and the live birth rate, it might represent a novel means to imp

226 The cumulative prognosis-adjusted live-birth rate across all cycles continued to increase

227 going IVF, the cumulative prognosis-adjusted live-birth rate after 6 cycles was 65.3%, with variation

228 Secondary outcomes included the live-birth rate and late pregnancy complications.

229 For women aged 40 to 42 years, the live-birth rate for the first cycle was 12.3% (95% CI, 1

230 In all women, the live-birth rate for the first cycle was 29.5% (95% CI, 2

231 r than 40 years using their own oocytes, the live-birth rate for the first cycle was 32.3% (95% CI, 3

232 continued due to poor prognosis and having a live-birth rate of 0 had they continued.

233 es achieving a cumulative prognosis-adjusted live-birth rate of 31.5% (95% CI, 29.7%-33.3%).

234 les achieved a cumulative prognosis-adjusted live-birth rate of 68.4% (95% CI, 67.8%-68.9%).

235 Live-birth rate per IVF cycle and the cumulative live-bi

236 sole diagnostic method (despite a favorable live-birth rate).

237 of 552 women in the water group (28.1%) had live births (rate ratio, 1.38; 95% CI, 1.17 to 1.64; P<0

238 7.8 years of follow-up (risk, 2.13 per 1000 live births; rate, 2.63/10000 child-years).

239 re ART treatment were associated with higher live birth rates among a population exposed to folic aci

240 is translated into an adjusted difference in live birth rates of 26% (95% CI: 10%, 48%; P = 0.02).

241 tensity and pregnancy outcomes emerged, with live birth rates of 48% in women dialyzed </=20 hours pe

242 Pregnancy outcomes including live birth rates, gestational age, and proportion of bab

243 reduce multiple gestations while maintaining live birth rates.

244 -birth rate per IVF cycle and the cumulative live-birth rates across all cycles in all women and by a

245 ections do not increase ongoing pregnancy or live-birth rates in women with unexplained RPL.

246 The live-birth rates were 86.0% (185 of 215 women) and 86.7%

247 gnosis-adjusted, and conservative cumulative live-birth rates were estimated, reflecting 0%, 30%, and

248 men with singleton pregnancies that ended in live birth, receipt of Tdap during pregnancy was not ass

249 tion of ovarian tissue has led to successful live births, reintroduction of latent malignant cells in

250 period increased from 64.0 to 77.9 per 1000 live births (relative rate, 1.22; 95% CI, 1.21-1.22 [P <

251 tract (CAKUT) occur in three to six of 1000 live births, represent about 20% of the prenatally detec

252 2.3)/1,000 births and 0.76 (0.25-1.77)/1,000 live births, respectively).

253 herited EB were 19.60 and 8.22 per 1 million live births, respectively.

254 y period were 55.2, 30.7, and 23.0 per 1,000 live births, respectively.

255 77 to 90] and 84 [95% CI, 78 to 90] per 1000 live births, respectively; P=0.002).

256 ions in preterm births (18.6 vs 21.8 per 100 live births; RR, 0.85; 95% CI, 0.80-0.91; P < .001) and

257 ) and low birth weight (40.2 vs 45.7 per 100 live births; RR, 0.88; 95% CI, 0.85-0.91; P < .001).

258 27 singleton stillbirths and 1,821 singleton live births studied, stillbirth was associated with SGA

259 n who received letrozole had more cumulative live births than those who received clomiphene (103 of 3

260 bined with LDA+LMWH was also associated with live births that occurred close to full term in all pati

261 -0.09) and a decline of 0.16 deaths per 1000 live births the following year (95% CI, -0.30 to -0.03).

262 According to national data for live births, the incidence of perinatal HIV infection am

263 urrent under-5 mortality rate is 54 per 1000 live births, the infant mortality rate is 46 per 1000 li

264 evalent birth defect, affecting nearly 1% of live births; the incidence of CHD is up to tenfold highe

265 pregnancies (189/194 [97.5%]) resulted in a live birth; there was no difference in birth outcomes ac

266 Live births to AYA cancer survivors may have an increase

267 0 to December 2014 to identify postdiagnosis live births to AYA survivors (n = 2598).

268 ery rates should not exceed 10 to 15 per 100 live births to optimize maternal and neonatal outcomes.

269 Twenty-one pregnancies (78%) resulted in a live birth, two preterm infants were stillborn, and four

270 rcentile) at death (stillbirth) or delivery (live birth) using population, ultrasound, and individual

271 Among the 4854 who had a live birth, vaccinated women were statistically signific

272 ; 66.6% of 138 who received enoxaparin had a live birth vs 72.9% of 118 who received placebo.

273 ervention arm (21.3 neonatal deaths per 1000 live births vs 30.1 per 1000 in control areas), a reduct

274 5 nonsmoking women who delivered a singleton live birth was carried out in Lanzhou, China, between 20

275 ere self-reported by women up to 5 y after a live birth was the main limitation.

276 The number of deaths per 1000 live births was 275 (95% confidence interval [CI], 264 t

277 an intention-to-treat analysis, the rate of live births was 65.8% (262 of 398 women) in the progeste

278 In this nationwide sample of live births we observed no association between induction

279 For live births, we identified 368 (29.3%) discordances betw

280 For 2015 live births, we used a compartmental model to estimate (

281 ollected in the first pregnancy leading to a live birth were eligible.

282 tion rate, embryo quality, implantation, and live birth were investigated using generalized linear mi

283 The diagnostic rate was 82.9%; unaffected live births were achieved in 9 of 20 FET cycles (45%), w

284 -encapsulated follicles resumed cycling, and live births were achieved only for follicles transplante

285 very rates of up to approximately 19 per 100 live births were associated with lower maternal or neona

286 Following exclusions, the 12,355,251 live births were classified by birthweight: 500-1,499 g

287 Rates of ongoing pregnancy and live births were higher among women who underwent hyster

288 arean delivery rates of 12.6 to 24.0 per 100 live births were inversely correlated with neonatal mort

289 ivery rates greater than 6.9 to 20.1 per 100 live births were inversely correlated with the maternal

290 Provincial live births were obtained from Statistics Canada.

291 r woman infected with Bundibugyo virus had a live birth with maternal and infant death in Isiro, the

292 The likelihood of achieving a live birth with repeat in vitro fertilization (IVF) is u

293 Of 214 live births with first-trimester exposure to second-gene

294 norms based on the subset of stillbirths and live births with non-missing variables showed similar fi

295 ion, in 797 offspring at age 5 y (82% of 973 live births) with the use of the McCarthy Scales of Chil

296 The infant mortality rate is 38 per 1000 live births, with deaths due mainly to perinatal and inf

297 y collected data on 6075 deaths among 22,248 live births, with gestational ages of 22 0/7 to 28 6/7 w

298 We conducted a retrospective cohort study of live births within Kaiser Permanente (KP) Georgia and Mi

299 A retrospective review of 290992 live births within the Intermountain Healthcare System i

300 man birth defect, affecting nearly 1% of all live births worldwide.